<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="letter" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">JHL</journal-id>
<journal-id journal-id-type="hwp">spjhl</journal-id>
<journal-id journal-id-type="nlm-ta">J Hum Lact</journal-id>
<journal-title>Journal of Human Lactation</journal-title>
<issn pub-type="ppub">0890-3344</issn>
<issn pub-type="epub">1552-5732</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0890334413483079</article-id>
<article-id pub-id-type="publisher-id">10.1177_0890334413483079</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Letters to the Editor</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Author Response to Dr Newman</article-title>
</title-group>
<contrib-group content-type="issue">
<contrib contrib-type="guest-editor">
<name><surname>Geddes</surname><given-names>Donna T.</given-names></name>
</contrib>
</contrib-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Anderson</surname><given-names>Philip O.</given-names></name>
<degrees>PharmD</degrees>
</contrib>
</contrib-group>
<pub-date pub-type="epub-ppub">
<month>5</month>
<year>2013</year>
</pub-date>
<volume>29</volume>
<issue>2</issue>
<issue-title>Special Issue: Breastfeeding Down Under</issue-title>
<fpage>263</fpage>
<lpage>264</lpage>
<permissions>
<copyright-statement>© The Author(s) 2013</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="sage">International Lactation Consultant Association</copyright-holder>
</permissions>
</article-meta>
</front>
<body>
<p>Dear Editor,</p>
<p>I believe that Dr Newman and I are not in great disagreement about the applicability to nursing mothers of the domperidone studies he cites. My point was that finding fault in studies that were not meant to address off-label use of domperidone in young women is not a substitute for studies designed to answer the questions of efficacy and safety in nursing mothers. However, the studies do serve as a signal that domperidone is capable of causing serious cardiac arrhythmias under certain conditions. Elevated serum drug concentration is generally accepted to be one of those conditions.<sup><xref ref-type="bibr" rid="bibr1-0890334413483079">1</xref></sup></p>
<p>With respect to when domperidone or other galactogogues should be used, the Academy of Breastfeeding Medicine (ABM), a group comprising physicians who “work hands on with mothers and babies who are having difficulty with breastfeeding,” has developed a clinical protocol on the use of galactogogues. The document states, “Medication should never replace evaluation and counseling on modifiable factors that affect milk production.”<sup><xref ref-type="bibr" rid="bibr2-0890334413483079">2</xref></sup> The statements by the ABM and Dr Newman fall into the category of expert opinion, which is not considered to be the highest level of evidence.<sup><xref ref-type="bibr" rid="bibr3-0890334413483079">3</xref></sup> More controlled clinical studies are needed to clarify the proper use of galactogogues.</p>
<p>Meanwhile, clinicians in the United States are left with the undesirable alternatives of either using metoclopramide or using domperidone from questionable sources as pharmaceutical galactogogues when they are needed. These are other good reasons to use the drugs very sparingly.</p>
<sig-block>
<sig><italic>Philip O. Anderson, PharmD</italic><break/><italic>Skaggs School of Pharmacy and Pharmaceutical Sciences</italic><break/><italic>University of California San Diego, La Jolla, California, USA</italic><break/><italic>Email: <email>phanderson@ucsd.edu</email></italic></sig>
</sig-block>
</body>
<back>
<ref-list>
<title>References</title>
<ref id="bibr1-0890334413483079">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kannankeril</surname><given-names>P</given-names></name>
<name><surname>Roden</surname><given-names>DM</given-names></name>
<name><surname>Darbar</surname><given-names>D</given-names></name>
</person-group>. <article-title>Drug-induced long QT syndrome</article-title>. <source>Pharmacol Rev</source>. <year>2010</year>;<volume>62</volume>(<issue>4</issue>):<fpage>760</fpage>-<lpage>781</lpage>.</citation>
</ref>
<ref id="bibr2-0890334413483079">
<label>2.</label>
<citation citation-type="journal">
<collab>Academy of Breastfeeding Medicine Protocol Committee</collab>. <article-title>ABM clinical protocol #9: use of galactogogues in initiating or augmenting the rate of maternal milk secretion (first revision January 2011)</article-title>. <source>Breastfeed Med</source>. <year>2011</year>;<volume>6</volume>(<issue>1</issue>):<fpage>41</fpage>-<lpage>49</lpage>.</citation>
</ref>
<ref id="bibr3-0890334413483079">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Balshem</surname><given-names>H</given-names></name>
<name><surname>Helfand</surname><given-names>M</given-names></name>
<name><surname>Schünemann</surname><given-names>HJ</given-names></name>
<etal/>
</person-group>. <article-title>GRADE guidelines: 3. Rating the quality of evidence</article-title>. <source>J Clin Epidemiol</source>. <year>2011</year>;<volume>64</volume>(<issue>4</issue>):<fpage>401</fpage>-<lpage>406</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>